| Name | Title | Contact Details |
|---|
Please select your location. United States International
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
Symphogen, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medicure, Inc. is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vilex is an innovative manufacturer of orthopaedic internal and external fixation devices, plates, and small joint implants.